nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—CYP1A1—Cholecalciferol—osteoporosis	0.0488	0.111	CbGbCtD
Carvedilol—CYP1A2—Estropipate—osteoporosis	0.0423	0.0965	CbGbCtD
Carvedilol—CYP1A1—Estradiol—osteoporosis	0.0394	0.0897	CbGbCtD
Carvedilol—CYP2C9—Estropipate—osteoporosis	0.0382	0.0869	CbGbCtD
Carvedilol—ABCB1—Ethinyl Estradiol—osteoporosis	0.0239	0.0544	CbGbCtD
Carvedilol—CYP3A4—Estropipate—osteoporosis	0.0222	0.0505	CbGbCtD
Carvedilol—CYP3A4—Calcitriol—osteoporosis	0.0222	0.0505	CbGbCtD
Carvedilol—CYP1A2—Conjugated Estrogens—osteoporosis	0.02	0.0456	CbGbCtD
Carvedilol—CYP2C9—Cholecalciferol—osteoporosis	0.0197	0.0448	CbGbCtD
Carvedilol—CYP2D6—Cholecalciferol—osteoporosis	0.018	0.041	CbGbCtD
Carvedilol—CYP3A4—Ergocalciferol—osteoporosis	0.0177	0.0404	CbGbCtD
Carvedilol—CYP1A2—Estradiol—osteoporosis	0.0176	0.0401	CbGbCtD
Carvedilol—ABCB1—Conjugated Estrogens—osteoporosis	0.0175	0.0399	CbGbCtD
Carvedilol—CYP2C9—Estradiol—osteoporosis	0.0158	0.0361	CbGbCtD
Carvedilol—ABCB1—Estradiol—osteoporosis	0.0154	0.035	CbGbCtD
Carvedilol—CYP3A4—Raloxifene—osteoporosis	0.0148	0.0337	CbGbCtD
Carvedilol—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0143	0.0326	CbGbCtD
Carvedilol—GJA1—periosteum—osteoporosis	0.0129	0.385	CbGeAlD
Carvedilol—CYP3A4—Cholecalciferol—osteoporosis	0.0114	0.026	CbGbCtD
Carvedilol—CYP3A4—Conjugated Estrogens—osteoporosis	0.0105	0.0239	CbGbCtD
Carvedilol—CYP3A4—Estradiol—osteoporosis	0.00921	0.021	CbGbCtD
Carvedilol—SELE—uterus—osteoporosis	0.00206	0.0613	CbGeAlD
Carvedilol—VCAM1—uterus—osteoporosis	0.0019	0.0564	CbGeAlD
Carvedilol—HIF1A—uterus—osteoporosis	0.00182	0.0542	CbGeAlD
Carvedilol—GJA1—uterus—osteoporosis	0.00177	0.0526	CbGeAlD
Carvedilol—VEGFA—Estradiol—Estropipate—osteoporosis	0.00174	0.418	CbGdCrCtD
Carvedilol—VCAM1—bone marrow—osteoporosis	0.00161	0.0479	CbGeAlD
Carvedilol—HIF1A—bone marrow—osteoporosis	0.00155	0.046	CbGeAlD
Carvedilol—NDUFC2—uterus—osteoporosis	0.00154	0.0458	CbGeAlD
Carvedilol—GJA1—bone marrow—osteoporosis	0.0015	0.0447	CbGeAlD
Carvedilol—VEGFA—uterus—osteoporosis	0.0014	0.0416	CbGeAlD
Carvedilol—VEGFA—Estradiol—Conjugated Estrogens—osteoporosis	0.00131	0.317	CbGdCrCtD
Carvedilol—NDUFC2—bone marrow—osteoporosis	0.00131	0.0389	CbGeAlD
Carvedilol—VEGFA—bone marrow—osteoporosis	0.00119	0.0353	CbGeAlD
Carvedilol—VEGFA—Estradiol—Ethinyl Estradiol—osteoporosis	0.0011	0.266	CbGdCrCtD
Carvedilol—KCNH2—uterus—osteoporosis	0.000506	0.0151	CbGeAlD
Carvedilol—ADRA2C—uterus—osteoporosis	0.000499	0.0149	CbGeAlD
Carvedilol—KCNH2—bone marrow—osteoporosis	0.00043	0.0128	CbGeAlD
Carvedilol—CYP1A1—uterus—osteoporosis	0.000428	0.0127	CbGeAlD
Carvedilol—ADRA2A—uterus—osteoporosis	0.000399	0.0119	CbGeAlD
Carvedilol—PTGS1—uterus—osteoporosis	0.000376	0.0112	CbGeAlD
Carvedilol—ABCB1—uterus—osteoporosis	0.000222	0.00661	CbGeAlD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000195	0.000651	CcSEcCtD
Carvedilol—Paraesthesia—Risedronate—osteoporosis	0.000194	0.00065	CcSEcCtD
Carvedilol—Pruritus—Estropipate—osteoporosis	0.000194	0.000648	CcSEcCtD
Carvedilol—Discomfort—Zoledronate—osteoporosis	0.000194	0.000647	CcSEcCtD
Carvedilol—Asthenia—Alendronate—osteoporosis	0.000193	0.000647	CcSEcCtD
Carvedilol—Hypersensitivity—Ibandronate—osteoporosis	0.000193	0.000647	CcSEcCtD
Carvedilol—Cough—Conjugated Estrogens—osteoporosis	0.000193	0.000647	CcSEcCtD
Carvedilol—Dyspnoea—Risedronate—osteoporosis	0.000193	0.000645	CcSEcCtD
Carvedilol—Erythema multiforme—Estradiol—osteoporosis	0.000193	0.000644	CcSEcCtD
Carvedilol—Hypotension—Pamidronate—osteoporosis	0.000192	0.000643	CcSEcCtD
Carvedilol—Convulsion—Conjugated Estrogens—osteoporosis	0.000192	0.000642	CcSEcCtD
Carvedilol—Dry mouth—Zoledronate—osteoporosis	0.000192	0.000641	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000192	0.00064	CcSEcCtD
Carvedilol—Fatigue—Ethinyl Estradiol—osteoporosis	0.000191	0.00064	CcSEcCtD
Carvedilol—Pruritus—Alendronate—osteoporosis	0.000191	0.000638	CcSEcCtD
Carvedilol—Dyspepsia—Risedronate—osteoporosis	0.00019	0.000637	CcSEcCtD
Carvedilol—Tinnitus—Estradiol—osteoporosis	0.00019	0.000635	CcSEcCtD
Carvedilol—Constipation—Ethinyl Estradiol—osteoporosis	0.00019	0.000634	CcSEcCtD
Carvedilol—Confusional state—Zoledronate—osteoporosis	0.000189	0.000633	CcSEcCtD
Carvedilol—Hypersensitivity—Calcitriol—osteoporosis	0.000189	0.000633	CcSEcCtD
Carvedilol—Chest pain—Conjugated Estrogens—osteoporosis	0.000189	0.000631	CcSEcCtD
Carvedilol—Myalgia—Conjugated Estrogens—osteoporosis	0.000189	0.000631	CcSEcCtD
Carvedilol—Arthralgia—Conjugated Estrogens—osteoporosis	0.000189	0.000631	CcSEcCtD
Carvedilol—ABCB1—bone marrow—osteoporosis	0.000188	0.00561	CbGeAlD
Carvedilol—Asthenia—Ibandronate—osteoporosis	0.000188	0.00063	CcSEcCtD
Carvedilol—Nausea—Etidronic acid—osteoporosis	0.000188	0.000628	CcSEcCtD
Carvedilol—Anaphylactic shock—Zoledronate—osteoporosis	0.000188	0.000628	CcSEcCtD
Carvedilol—Oedema—Zoledronate—osteoporosis	0.000188	0.000628	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000187	0.000627	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000187	0.000626	CcSEcCtD
Carvedilol—Diarrhoea—Estropipate—osteoporosis	0.000187	0.000626	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Risedronate—osteoporosis	0.000187	0.000624	CcSEcCtD
Carvedilol—Infection—Zoledronate—osteoporosis	0.000187	0.000624	CcSEcCtD
Carvedilol—Fatigue—Risedronate—osteoporosis	0.000186	0.000624	CcSEcCtD
Carvedilol—Insomnia—Pamidronate—osteoporosis	0.000186	0.000622	CcSEcCtD
Carvedilol—Pruritus—Ibandronate—osteoporosis	0.000186	0.000621	CcSEcCtD
Carvedilol—Pain—Risedronate—osteoporosis	0.000185	0.000619	CcSEcCtD
Carvedilol—Constipation—Risedronate—osteoporosis	0.000185	0.000619	CcSEcCtD
Carvedilol—Angiopathy—Estradiol—osteoporosis	0.000185	0.000618	CcSEcCtD
Carvedilol—Shock—Zoledronate—osteoporosis	0.000185	0.000618	CcSEcCtD
Carvedilol—Paraesthesia—Pamidronate—osteoporosis	0.000185	0.000617	CcSEcCtD
Carvedilol—Diarrhoea—Alendronate—osteoporosis	0.000184	0.000617	CcSEcCtD
Carvedilol—Asthenia—Calcitriol—osteoporosis	0.000184	0.000616	CcSEcCtD
Carvedilol—Immune system disorder—Estradiol—osteoporosis	0.000184	0.000615	CcSEcCtD
Carvedilol—Thrombocytopenia—Zoledronate—osteoporosis	0.000184	0.000615	CcSEcCtD
Carvedilol—Mediastinal disorder—Estradiol—osteoporosis	0.000184	0.000614	CcSEcCtD
Carvedilol—Dyspnoea—Pamidronate—osteoporosis	0.000183	0.000613	CcSEcCtD
Carvedilol—Tachycardia—Zoledronate—osteoporosis	0.000183	0.000613	CcSEcCtD
Carvedilol—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000183	0.000611	CcSEcCtD
Carvedilol—Somnolence—Pamidronate—osteoporosis	0.000183	0.000611	CcSEcCtD
Carvedilol—Skin disorder—Zoledronate—osteoporosis	0.000182	0.00061	CcSEcCtD
Carvedilol—Pruritus—Calcitriol—osteoporosis	0.000182	0.000608	CcSEcCtD
Carvedilol—Hyperhidrosis—Zoledronate—osteoporosis	0.000182	0.000607	CcSEcCtD
Carvedilol—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000181	0.000607	CcSEcCtD
Carvedilol—Diarrhoea—Raloxifene—osteoporosis	0.000181	0.000607	CcSEcCtD
Carvedilol—Dyspepsia—Pamidronate—osteoporosis	0.000181	0.000605	CcSEcCtD
Carvedilol—Dizziness—Estropipate—osteoporosis	0.000181	0.000605	CcSEcCtD
Carvedilol—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000181	0.000605	CcSEcCtD
Carvedilol—Oedema—Conjugated Estrogens—osteoporosis	0.000181	0.000605	CcSEcCtD
Carvedilol—Alopecia—Estradiol—osteoporosis	0.00018	0.000602	CcSEcCtD
Carvedilol—Infection—Conjugated Estrogens—osteoporosis	0.00018	0.000601	CcSEcCtD
Carvedilol—Diarrhoea—Ibandronate—osteoporosis	0.00018	0.000601	CcSEcCtD
Carvedilol—Anorexia—Zoledronate—osteoporosis	0.000179	0.000599	CcSEcCtD
Carvedilol—Decreased appetite—Pamidronate—osteoporosis	0.000179	0.000598	CcSEcCtD
Carvedilol—Dizziness—Alendronate—osteoporosis	0.000178	0.000596	CcSEcCtD
Carvedilol—Shock—Conjugated Estrogens—osteoporosis	0.000178	0.000595	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000178	0.000594	CcSEcCtD
Carvedilol—Malnutrition—Estradiol—osteoporosis	0.000177	0.000593	CcSEcCtD
Carvedilol—Fatigue—Pamidronate—osteoporosis	0.000177	0.000593	CcSEcCtD
Carvedilol—Gastrointestinal pain—Risedronate—osteoporosis	0.000177	0.000591	CcSEcCtD
Carvedilol—Tachycardia—Conjugated Estrogens—osteoporosis	0.000177	0.00059	CcSEcCtD
Carvedilol—Urticaria—Ethinyl Estradiol—osteoporosis	0.000176	0.000589	CcSEcCtD
Carvedilol—Constipation—Pamidronate—osteoporosis	0.000176	0.000588	CcSEcCtD
Carvedilol—Pain—Pamidronate—osteoporosis	0.000176	0.000588	CcSEcCtD
Carvedilol—Diarrhoea—Calcitriol—osteoporosis	0.000176	0.000588	CcSEcCtD
Carvedilol—Skin disorder—Conjugated Estrogens—osteoporosis	0.000176	0.000587	CcSEcCtD
Carvedilol—Hypotension—Zoledronate—osteoporosis	0.000176	0.000587	CcSEcCtD
Carvedilol—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000175	0.000586	CcSEcCtD
Carvedilol—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000175	0.000586	CcSEcCtD
Carvedilol—Dizziness—Raloxifene—osteoporosis	0.000175	0.000586	CcSEcCtD
Carvedilol—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000175	0.000585	CcSEcCtD
Carvedilol—Flatulence—Estradiol—osteoporosis	0.000175	0.000584	CcSEcCtD
Carvedilol—Tension—Estradiol—osteoporosis	0.000174	0.000582	CcSEcCtD
Carvedilol—Vomiting—Estropipate—osteoporosis	0.000174	0.000582	CcSEcCtD
Carvedilol—Dizziness—Ibandronate—osteoporosis	0.000174	0.00058	CcSEcCtD
Carvedilol—Rash—Estropipate—osteoporosis	0.000173	0.000577	CcSEcCtD
Carvedilol—Dermatitis—Estropipate—osteoporosis	0.000172	0.000577	CcSEcCtD
Carvedilol—Anorexia—Conjugated Estrogens—osteoporosis	0.000172	0.000576	CcSEcCtD
Carvedilol—Nervousness—Estradiol—osteoporosis	0.000172	0.000576	CcSEcCtD
Carvedilol—Urticaria—Risedronate—osteoporosis	0.000172	0.000575	CcSEcCtD
Carvedilol—Back pain—Estradiol—osteoporosis	0.000172	0.000574	CcSEcCtD
Carvedilol—Headache—Estropipate—osteoporosis	0.000171	0.000573	CcSEcCtD
Carvedilol—Vomiting—Alendronate—osteoporosis	0.000171	0.000573	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000171	0.000572	CcSEcCtD
Carvedilol—Abdominal pain—Risedronate—osteoporosis	0.000171	0.000572	CcSEcCtD
Carvedilol—Body temperature increased—Risedronate—osteoporosis	0.000171	0.000572	CcSEcCtD
Carvedilol—Muscle spasms—Estradiol—osteoporosis	0.000171	0.00057	CcSEcCtD
Carvedilol—Rash—Alendronate—osteoporosis	0.00017	0.000568	CcSEcCtD
Carvedilol—Insomnia—Zoledronate—osteoporosis	0.00017	0.000568	CcSEcCtD
Carvedilol—Dermatitis—Alendronate—osteoporosis	0.00017	0.000568	CcSEcCtD
Carvedilol—Feeling abnormal—Pamidronate—osteoporosis	0.000169	0.000567	CcSEcCtD
Carvedilol—Hypotension—Conjugated Estrogens—osteoporosis	0.000169	0.000565	CcSEcCtD
Carvedilol—Headache—Alendronate—osteoporosis	0.000169	0.000565	CcSEcCtD
Carvedilol—Paraesthesia—Zoledronate—osteoporosis	0.000169	0.000564	CcSEcCtD
Carvedilol—Vomiting—Raloxifene—osteoporosis	0.000169	0.000564	CcSEcCtD
Carvedilol—Gastrointestinal pain—Pamidronate—osteoporosis	0.000168	0.000562	CcSEcCtD
Carvedilol—Dyspnoea—Zoledronate—osteoporosis	0.000167	0.00056	CcSEcCtD
Carvedilol—Rash—Raloxifene—osteoporosis	0.000167	0.000559	CcSEcCtD
Carvedilol—Dermatitis—Raloxifene—osteoporosis	0.000167	0.000558	CcSEcCtD
Carvedilol—Somnolence—Zoledronate—osteoporosis	0.000167	0.000558	CcSEcCtD
Carvedilol—Vomiting—Ibandronate—osteoporosis	0.000167	0.000558	CcSEcCtD
Carvedilol—Headache—Raloxifene—osteoporosis	0.000166	0.000555	CcSEcCtD
Carvedilol—Rash—Ibandronate—osteoporosis	0.000165	0.000553	CcSEcCtD
Carvedilol—Dermatitis—Ibandronate—osteoporosis	0.000165	0.000553	CcSEcCtD
Carvedilol—Dyspepsia—Zoledronate—osteoporosis	0.000165	0.000553	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000165	0.000551	CcSEcCtD
Carvedilol—Ill-defined disorder—Estradiol—osteoporosis	0.000165	0.00055	CcSEcCtD
Carvedilol—Headache—Ibandronate—osteoporosis	0.000164	0.00055	CcSEcCtD
Carvedilol—Insomnia—Conjugated Estrogens—osteoporosis	0.000164	0.000547	CcSEcCtD
Carvedilol—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000163	0.000547	CcSEcCtD
Carvedilol—Vomiting—Calcitriol—osteoporosis	0.000163	0.000546	CcSEcCtD
Carvedilol—Decreased appetite—Zoledronate—osteoporosis	0.000163	0.000546	CcSEcCtD
Carvedilol—Nausea—Estropipate—osteoporosis	0.000163	0.000544	CcSEcCtD
Carvedilol—Abdominal pain—Pamidronate—osteoporosis	0.000163	0.000544	CcSEcCtD
Carvedilol—Body temperature increased—Pamidronate—osteoporosis	0.000163	0.000544	CcSEcCtD
Carvedilol—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000162	0.000543	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000162	0.000542	CcSEcCtD
Carvedilol—Angioedema—Estradiol—osteoporosis	0.000162	0.000542	CcSEcCtD
Carvedilol—Rash—Calcitriol—osteoporosis	0.000162	0.000542	CcSEcCtD
Carvedilol—Fatigue—Zoledronate—osteoporosis	0.000162	0.000542	CcSEcCtD
Carvedilol—Dermatitis—Calcitriol—osteoporosis	0.000162	0.000541	CcSEcCtD
Carvedilol—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000161	0.000539	CcSEcCtD
Carvedilol—Headache—Calcitriol—osteoporosis	0.000161	0.000538	CcSEcCtD
Carvedilol—Somnolence—Conjugated Estrogens—osteoporosis	0.000161	0.000538	CcSEcCtD
Carvedilol—Pain—Zoledronate—osteoporosis	0.000161	0.000537	CcSEcCtD
Carvedilol—Constipation—Zoledronate—osteoporosis	0.000161	0.000537	CcSEcCtD
Carvedilol—Nausea—Alendronate—osteoporosis	0.00016	0.000535	CcSEcCtD
Carvedilol—Malaise—Estradiol—osteoporosis	0.00016	0.000535	CcSEcCtD
Carvedilol—Hypersensitivity—Risedronate—osteoporosis	0.000159	0.000533	CcSEcCtD
Carvedilol—Vertigo—Estradiol—osteoporosis	0.000159	0.000533	CcSEcCtD
Carvedilol—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000159	0.000532	CcSEcCtD
Carvedilol—Asthenia—Ethinyl Estradiol—osteoporosis	0.000159	0.000532	CcSEcCtD
Carvedilol—Syncope—Estradiol—osteoporosis	0.000159	0.000532	CcSEcCtD
Carvedilol—Nausea—Raloxifene—osteoporosis	0.000157	0.000527	CcSEcCtD
Carvedilol—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000157	0.000526	CcSEcCtD
Carvedilol—Pruritus—Ethinyl Estradiol—osteoporosis	0.000157	0.000525	CcSEcCtD
Carvedilol—Palpitations—Estradiol—osteoporosis	0.000157	0.000524	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000156	0.000522	CcSEcCtD
Carvedilol—Fatigue—Conjugated Estrogens—osteoporosis	0.000156	0.000521	CcSEcCtD
Carvedilol—Nausea—Ibandronate—osteoporosis	0.000156	0.000521	CcSEcCtD
Carvedilol—Loss of consciousness—Estradiol—osteoporosis	0.000156	0.000521	CcSEcCtD
Carvedilol—Asthenia—Risedronate—osteoporosis	0.000155	0.000519	CcSEcCtD
Carvedilol—Feeling abnormal—Zoledronate—osteoporosis	0.000155	0.000518	CcSEcCtD
Carvedilol—Cough—Estradiol—osteoporosis	0.000155	0.000518	CcSEcCtD
Carvedilol—Pain—Conjugated Estrogens—osteoporosis	0.000155	0.000517	CcSEcCtD
Carvedilol—Constipation—Conjugated Estrogens—osteoporosis	0.000155	0.000517	CcSEcCtD
Carvedilol—Gastrointestinal pain—Zoledronate—osteoporosis	0.000154	0.000514	CcSEcCtD
Carvedilol—Hypertension—Estradiol—osteoporosis	0.000153	0.000512	CcSEcCtD
Carvedilol—Pruritus—Risedronate—osteoporosis	0.000153	0.000512	CcSEcCtD
Carvedilol—Nausea—Calcitriol—osteoporosis	0.000153	0.00051	CcSEcCtD
Carvedilol—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000152	0.000508	CcSEcCtD
Carvedilol—Hypersensitivity—Pamidronate—osteoporosis	0.000151	0.000507	CcSEcCtD
Carvedilol—Arthralgia—Estradiol—osteoporosis	0.000151	0.000505	CcSEcCtD
Carvedilol—Chest pain—Estradiol—osteoporosis	0.000151	0.000505	CcSEcCtD
Carvedilol—Myalgia—Estradiol—osteoporosis	0.000151	0.000505	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00015	0.000501	CcSEcCtD
Carvedilol—Urticaria—Zoledronate—osteoporosis	0.000149	0.000499	CcSEcCtD
Carvedilol—Discomfort—Estradiol—osteoporosis	0.000149	0.000499	CcSEcCtD
Carvedilol—Body temperature increased—Zoledronate—osteoporosis	0.000148	0.000497	CcSEcCtD
Carvedilol—Abdominal pain—Zoledronate—osteoporosis	0.000148	0.000497	CcSEcCtD
Carvedilol—Diarrhoea—Risedronate—osteoporosis	0.000148	0.000495	CcSEcCtD
Carvedilol—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000148	0.000495	CcSEcCtD
Carvedilol—Dry mouth—Estradiol—osteoporosis	0.000148	0.000494	CcSEcCtD
Carvedilol—Asthenia—Pamidronate—osteoporosis	0.000148	0.000493	CcSEcCtD
Carvedilol—Dizziness—Ethinyl Estradiol—osteoporosis	0.000147	0.000491	CcSEcCtD
Carvedilol—Confusional state—Estradiol—osteoporosis	0.000146	0.000488	CcSEcCtD
Carvedilol—Pruritus—Pamidronate—osteoporosis	0.000145	0.000486	CcSEcCtD
Carvedilol—Oedema—Estradiol—osteoporosis	0.000145	0.000484	CcSEcCtD
Carvedilol—Anaphylactic shock—Estradiol—osteoporosis	0.000145	0.000484	CcSEcCtD
Carvedilol—Infection—Estradiol—osteoporosis	0.000144	0.000481	CcSEcCtD
Carvedilol—Urticaria—Conjugated Estrogens—osteoporosis	0.000144	0.00048	CcSEcCtD
Carvedilol—Dizziness—Risedronate—osteoporosis	0.000143	0.000478	CcSEcCtD
Carvedilol—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000143	0.000478	CcSEcCtD
Carvedilol—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000143	0.000478	CcSEcCtD
Carvedilol—Shock—Estradiol—osteoporosis	0.000142	0.000476	CcSEcCtD
Carvedilol—Tachycardia—Estradiol—osteoporosis	0.000141	0.000472	CcSEcCtD
Carvedilol—Vomiting—Ethinyl Estradiol—osteoporosis	0.000141	0.000472	CcSEcCtD
Carvedilol—Diarrhoea—Pamidronate—osteoporosis	0.000141	0.00047	CcSEcCtD
Carvedilol—Skin disorder—Estradiol—osteoporosis	0.000141	0.00047	CcSEcCtD
Carvedilol—Hyperhidrosis—Estradiol—osteoporosis	0.00014	0.000468	CcSEcCtD
Carvedilol—Rash—Ethinyl Estradiol—osteoporosis	0.00014	0.000468	CcSEcCtD
Carvedilol—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00014	0.000467	CcSEcCtD
Carvedilol—Headache—Ethinyl Estradiol—osteoporosis	0.000139	0.000465	CcSEcCtD
Carvedilol—Hypersensitivity—Zoledronate—osteoporosis	0.000138	0.000463	CcSEcCtD
Carvedilol—Vomiting—Risedronate—osteoporosis	0.000138	0.00046	CcSEcCtD
Carvedilol—Rash—Risedronate—osteoporosis	0.000136	0.000456	CcSEcCtD
Carvedilol—Dermatitis—Risedronate—osteoporosis	0.000136	0.000456	CcSEcCtD
Carvedilol—Dizziness—Pamidronate—osteoporosis	0.000136	0.000455	CcSEcCtD
Carvedilol—Headache—Risedronate—osteoporosis	0.000136	0.000453	CcSEcCtD
Carvedilol—Asthenia—Zoledronate—osteoporosis	0.000135	0.000451	CcSEcCtD
Carvedilol—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000133	0.000446	CcSEcCtD
Carvedilol—Pruritus—Zoledronate—osteoporosis	0.000133	0.000444	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000132	0.000441	CcSEcCtD
Carvedilol—Nausea—Ethinyl Estradiol—osteoporosis	0.000132	0.000441	CcSEcCtD
Carvedilol—Insomnia—Estradiol—osteoporosis	0.000131	0.000438	CcSEcCtD
Carvedilol—Vomiting—Pamidronate—osteoporosis	0.000131	0.000437	CcSEcCtD
Carvedilol—Paraesthesia—Estradiol—osteoporosis	0.00013	0.000435	CcSEcCtD
Carvedilol—Asthenia—Conjugated Estrogens—osteoporosis	0.00013	0.000434	CcSEcCtD
Carvedilol—Rash—Pamidronate—osteoporosis	0.00013	0.000434	CcSEcCtD
Carvedilol—Dermatitis—Pamidronate—osteoporosis	0.00013	0.000433	CcSEcCtD
Carvedilol—Dyspnoea—Estradiol—osteoporosis	0.000129	0.000432	CcSEcCtD
Carvedilol—Headache—Pamidronate—osteoporosis	0.000129	0.000431	CcSEcCtD
Carvedilol—Somnolence—Estradiol—osteoporosis	0.000129	0.00043	CcSEcCtD
Carvedilol—Diarrhoea—Zoledronate—osteoporosis	0.000129	0.00043	CcSEcCtD
Carvedilol—Nausea—Risedronate—osteoporosis	0.000128	0.00043	CcSEcCtD
Carvedilol—Pruritus—Conjugated Estrogens—osteoporosis	0.000128	0.000428	CcSEcCtD
Carvedilol—Dyspepsia—Estradiol—osteoporosis	0.000127	0.000426	CcSEcCtD
Carvedilol—Decreased appetite—Estradiol—osteoporosis	0.000126	0.000421	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Estradiol—osteoporosis	0.000125	0.000418	CcSEcCtD
Carvedilol—Fatigue—Estradiol—osteoporosis	0.000125	0.000417	CcSEcCtD
Carvedilol—Dizziness—Zoledronate—osteoporosis	0.000124	0.000415	CcSEcCtD
Carvedilol—Pain—Estradiol—osteoporosis	0.000124	0.000414	CcSEcCtD
Carvedilol—Constipation—Estradiol—osteoporosis	0.000124	0.000414	CcSEcCtD
Carvedilol—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000124	0.000414	CcSEcCtD
Carvedilol—Nausea—Pamidronate—osteoporosis	0.000122	0.000408	CcSEcCtD
Carvedilol—Dizziness—Conjugated Estrogens—osteoporosis	0.00012	0.0004	CcSEcCtD
Carvedilol—Vomiting—Zoledronate—osteoporosis	0.000119	0.000399	CcSEcCtD
Carvedilol—Feeling abnormal—Estradiol—osteoporosis	0.000119	0.000399	CcSEcCtD
Carvedilol—Rash—Zoledronate—osteoporosis	0.000118	0.000396	CcSEcCtD
Carvedilol—Gastrointestinal pain—Estradiol—osteoporosis	0.000118	0.000396	CcSEcCtD
Carvedilol—Dermatitis—Zoledronate—osteoporosis	0.000118	0.000396	CcSEcCtD
Carvedilol—Headache—Zoledronate—osteoporosis	0.000118	0.000393	CcSEcCtD
Carvedilol—Vomiting—Conjugated Estrogens—osteoporosis	0.000115	0.000385	CcSEcCtD
Carvedilol—Urticaria—Estradiol—osteoporosis	0.000115	0.000385	CcSEcCtD
Carvedilol—Abdominal pain—Estradiol—osteoporosis	0.000114	0.000383	CcSEcCtD
Carvedilol—Body temperature increased—Estradiol—osteoporosis	0.000114	0.000383	CcSEcCtD
Carvedilol—Rash—Conjugated Estrogens—osteoporosis	0.000114	0.000381	CcSEcCtD
Carvedilol—Dermatitis—Conjugated Estrogens—osteoporosis	0.000114	0.000381	CcSEcCtD
Carvedilol—Headache—Conjugated Estrogens—osteoporosis	0.000113	0.000379	CcSEcCtD
Carvedilol—Nausea—Zoledronate—osteoporosis	0.000112	0.000373	CcSEcCtD
Carvedilol—Nausea—Conjugated Estrogens—osteoporosis	0.000107	0.000359	CcSEcCtD
Carvedilol—Hypersensitivity—Estradiol—osteoporosis	0.000107	0.000357	CcSEcCtD
Carvedilol—Asthenia—Estradiol—osteoporosis	0.000104	0.000347	CcSEcCtD
Carvedilol—Pruritus—Estradiol—osteoporosis	0.000102	0.000342	CcSEcCtD
Carvedilol—Diarrhoea—Estradiol—osteoporosis	9.9e-05	0.000331	CcSEcCtD
Carvedilol—Dizziness—Estradiol—osteoporosis	9.57e-05	0.00032	CcSEcCtD
Carvedilol—Vomiting—Estradiol—osteoporosis	9.2e-05	0.000308	CcSEcCtD
Carvedilol—Rash—Estradiol—osteoporosis	9.13e-05	0.000305	CcSEcCtD
Carvedilol—Dermatitis—Estradiol—osteoporosis	9.12e-05	0.000305	CcSEcCtD
Carvedilol—Headache—Estradiol—osteoporosis	9.07e-05	0.000303	CcSEcCtD
Carvedilol—Nausea—Estradiol—osteoporosis	8.6e-05	0.000288	CcSEcCtD
Carvedilol—ADRB2—Signaling Pathways—KL—osteoporosis	1.11e-05	4.97e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PSMA2—osteoporosis	1.11e-05	4.95e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PSMA5—osteoporosis	1.11e-05	4.95e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—IL6—osteoporosis	1.11e-05	4.95e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—POMC—osteoporosis	1.11e-05	4.95e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TGFB1—osteoporosis	1.11e-05	4.93e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—POMC—osteoporosis	1.11e-05	4.93e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—POMC—osteoporosis	1.1e-05	4.92e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—TPI1—osteoporosis	1.1e-05	4.91e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—POMC—osteoporosis	1.1e-05	4.91e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—P4HB—osteoporosis	1.1e-05	4.9e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—IDH2—osteoporosis	1.1e-05	4.89e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—TPI1—osteoporosis	1.09e-05	4.87e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PSMA5—osteoporosis	1.09e-05	4.85e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PSMA2—osteoporosis	1.09e-05	4.85e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—POMC—osteoporosis	1.09e-05	4.84e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL6R—osteoporosis	1.08e-05	4.83e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GAPDH—osteoporosis	1.08e-05	4.81e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL6R—osteoporosis	1.08e-05	4.81e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6R—osteoporosis	1.08e-05	4.8e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6R—osteoporosis	1.07e-05	4.79e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTHLH—osteoporosis	1.07e-05	4.77e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—BMP2—osteoporosis	1.07e-05	4.77e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IGF1—osteoporosis	1.06e-05	4.74e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ENO1—osteoporosis	1.06e-05	4.74e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IGF1—osteoporosis	1.06e-05	4.73e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6R—osteoporosis	1.06e-05	4.72e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KL—osteoporosis	1.05e-05	4.7e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—RAP1A—osteoporosis	1.05e-05	4.68e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FGB—osteoporosis	1.05e-05	4.67e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PSMA2—osteoporosis	1.05e-05	4.67e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PSMA5—osteoporosis	1.05e-05	4.67e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KL—osteoporosis	1.04e-05	4.62e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—P4HB—osteoporosis	1.03e-05	4.62e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TGFB1—osteoporosis	1.03e-05	4.6e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP27A1—osteoporosis	1.03e-05	4.6e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—POMC—osteoporosis	1.03e-05	4.58e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—P4HB—osteoporosis	1.03e-05	4.58e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—OXCT1—osteoporosis	1.02e-05	4.55e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CA2—osteoporosis	1.02e-05	4.55e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GAPDH—osteoporosis	1.02e-05	4.53e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CALCA—osteoporosis	1.01e-05	4.52e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—POMC—osteoporosis	1.01e-05	4.51e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PSMA5—osteoporosis	1.01e-05	4.51e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PSMA2—osteoporosis	1.01e-05	4.51e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GAPDH—osteoporosis	1.01e-05	4.49e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ACP5—osteoporosis	1e-05	4.47e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6R—osteoporosis	1e-05	4.47e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MGLL—osteoporosis	9.95e-06	4.44e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	9.9e-06	4.42e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—RAP1A—osteoporosis	9.89e-06	4.41e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—POMC—osteoporosis	9.89e-06	4.41e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ADCY5—osteoporosis	9.87e-06	4.4e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6R—osteoporosis	9.87e-06	4.4e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ADCY5—osteoporosis	9.85e-06	4.39e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—GPX1—osteoporosis	9.84e-06	4.39e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—GPX1—osteoporosis	9.82e-06	4.38e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CYP19A1—osteoporosis	9.81e-06	4.38e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—RAP1A—osteoporosis	9.81e-06	4.37e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ADCY5—osteoporosis	9.79e-06	4.36e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SPP1—osteoporosis	9.47e-06	4.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CALCA—osteoporosis	9.42e-06	4.2e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TPI1—osteoporosis	9.33e-06	4.16e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KL—osteoporosis	9.21e-06	4.11e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—POMC—osteoporosis	9.19e-06	4.1e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—MTHFR—osteoporosis	9.08e-06	4.05e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—MTHFR—osteoporosis	9.06e-06	4.04e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CYP19A1—osteoporosis	9.01e-06	4.02e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—POMC—osteoporosis	8.98e-06	4.01e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ADCY5—osteoporosis	8.92e-06	3.98e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ADCY5—osteoporosis	8.84e-06	3.94e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—P4HB—osteoporosis	8.77e-06	3.91e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6R—osteoporosis	8.76e-06	3.91e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ADCY5—osteoporosis	8.72e-06	3.89e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SPP1—osteoporosis	8.63e-06	3.85e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GAPDH—osteoporosis	8.61e-06	3.84e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IRS2—osteoporosis	8.56e-06	3.82e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KL—osteoporosis	8.56e-06	3.82e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	8.55e-06	3.81e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SPP1—osteoporosis	8.55e-06	3.81e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CYP19A1—osteoporosis	8.49e-06	3.79e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ENO1—osteoporosis	8.49e-06	3.78e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—IDH2—osteoporosis	8.46e-06	3.77e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SPP1—osteoporosis	8.44e-06	3.76e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TGFB1—osteoporosis	8.39e-06	3.74e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—RAP1A—osteoporosis	8.38e-06	3.74e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—LEP—osteoporosis	8.38e-06	3.74e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PSMA5—osteoporosis	8.36e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PSMA2—osteoporosis	8.36e-06	3.73e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—POMC—osteoporosis	8.35e-06	3.72e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ADCY5—osteoporosis	8.25e-06	3.68e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6R—osteoporosis	8.14e-06	3.63e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—IL6—osteoporosis	8.13e-06	3.62e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ADCY5—osteoporosis	8.12e-06	3.62e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ADCY5—osteoporosis	8.02e-06	3.58e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ESR1—osteoporosis	8e-06	3.57e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ENO1—osteoporosis	8e-06	3.57e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—GPX1—osteoporosis	7.99e-06	3.56e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SPP1—osteoporosis	7.98e-06	3.56e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP27A1—osteoporosis	7.96e-06	3.55e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ENO1—osteoporosis	7.93e-06	3.54e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PSMA2—osteoporosis	7.88e-06	3.51e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PSMA5—osteoporosis	7.88e-06	3.51e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SPP1—osteoporosis	7.86e-06	3.5e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PSMA2—osteoporosis	7.81e-06	3.48e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PSMA5—osteoporosis	7.81e-06	3.48e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IRS2—osteoporosis	7.8e-06	3.48e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ACP5—osteoporosis	7.74e-06	3.45e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IRS2—osteoporosis	7.73e-06	3.45e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—LEP—osteoporosis	7.63e-06	3.4e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IRS2—osteoporosis	7.63e-06	3.4e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—LEP—osteoporosis	7.57e-06	3.37e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IRS1—osteoporosis	7.48e-06	3.33e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—LEP—osteoporosis	7.47e-06	3.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—MTHFR—osteoporosis	7.37e-06	3.29e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ADCY5—osteoporosis	7.36e-06	3.28e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—GPX1—osteoporosis	7.34e-06	3.27e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	7.31e-06	3.26e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ESR1—osteoporosis	7.29e-06	3.25e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—POMC—osteoporosis	7.26e-06	3.24e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—POMC—osteoporosis	7.25e-06	3.23e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ESR1—osteoporosis	7.22e-06	3.22e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IRS2—osteoporosis	7.22e-06	3.22e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ADCY5—osteoporosis	7.21e-06	3.22e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—POMC—osteoporosis	7.2e-06	3.21e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TPI1—osteoporosis	7.2e-06	3.21e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ESR1—osteoporosis	7.13e-06	3.18e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IRS2—osteoporosis	7.11e-06	3.17e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—LEP—osteoporosis	7.07e-06	3.15e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6R—osteoporosis	7.02e-06	3.13e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SPP1—osteoporosis	6.98e-06	3.11e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—LEP—osteoporosis	6.95e-06	3.1e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ADCY5—osteoporosis	6.94e-06	3.1e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IGF1—osteoporosis	6.92e-06	3.09e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—GPX1—osteoporosis	6.92e-06	3.08e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IRS1—osteoporosis	6.81e-06	3.04e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CYP19A1—osteoporosis	6.79e-06	3.03e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ENO1—osteoporosis	6.78e-06	3.02e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—MTHFR—osteoporosis	6.77e-06	3.02e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—P4HB—osteoporosis	6.77e-06	3.02e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IRS1—osteoporosis	6.75e-06	3.01e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ESR1—osteoporosis	6.75e-06	3.01e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	6.7e-06	2.99e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PSMA5—osteoporosis	6.68e-06	2.98e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PSMA2—osteoporosis	6.68e-06	2.98e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IRS1—osteoporosis	6.66e-06	2.97e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GAPDH—osteoporosis	6.64e-06	2.96e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ESR1—osteoporosis	6.64e-06	2.96e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—POMC—osteoporosis	6.56e-06	2.92e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—POMC—osteoporosis	6.5e-06	2.9e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SPP1—osteoporosis	6.49e-06	2.89e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—RAP1A—osteoporosis	6.47e-06	2.88e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—POMC—osteoporosis	6.42e-06	2.86e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6R—osteoporosis	6.4e-06	2.85e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CYP19A1—osteoporosis	6.39e-06	2.85e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MYC—osteoporosis	6.39e-06	2.85e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—MTHFR—osteoporosis	6.38e-06	2.85e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MYC—osteoporosis	6.37e-06	2.84e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TGFB1—osteoporosis	6.37e-06	2.84e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TGFB1—osteoporosis	6.36e-06	2.84e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6R—osteoporosis	6.34e-06	2.83e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CYP19A1—osteoporosis	6.34e-06	2.83e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IRS2—osteoporosis	6.31e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IGF1—osteoporosis	6.31e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IRS1—osteoporosis	6.3e-06	2.81e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6R—osteoporosis	6.26e-06	2.79e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IGF1—osteoporosis	6.25e-06	2.79e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IRS1—osteoporosis	6.2e-06	2.77e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—LEP—osteoporosis	6.18e-06	2.75e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IGF1—osteoporosis	6.17e-06	2.75e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—POMC—osteoporosis	6.07e-06	2.71e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—POMC—osteoporosis	5.97e-06	2.66e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6R—osteoporosis	5.92e-06	2.64e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ESR1—osteoporosis	5.9e-06	2.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—POMC—osteoporosis	5.9e-06	2.63e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IRS2—osteoporosis	5.87e-06	2.62e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IGF1—osteoporosis	5.84e-06	2.6e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6R—osteoporosis	5.83e-06	2.6e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IGF1—osteoporosis	5.75e-06	2.56e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—LEP—osteoporosis	5.74e-06	2.56e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ADCY5—osteoporosis	5.54e-06	2.47e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GPX1—osteoporosis	5.52e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IRS1—osteoporosis	5.51e-06	2.46e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ESR1—osteoporosis	5.48e-06	2.44e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP19A1—osteoporosis	5.42e-06	2.42e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—POMC—osteoporosis	5.42e-06	2.41e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—POMC—osteoporosis	5.31e-06	2.37e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL6—osteoporosis	5.3e-06	2.36e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ENO1—osteoporosis	5.23e-06	2.33e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ADCY5—osteoporosis	5.22e-06	2.33e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GPX1—osteoporosis	5.21e-06	2.32e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ADCY5—osteoporosis	5.18e-06	2.31e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6R—osteoporosis	5.18e-06	2.31e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GPX1—osteoporosis	5.16e-06	2.3e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PSMA2—osteoporosis	5.15e-06	2.3e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PSMA5—osteoporosis	5.15e-06	2.3e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IRS1—osteoporosis	5.12e-06	2.28e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—POMC—osteoporosis	5.11e-06	2.28e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IGF1—osteoporosis	5.1e-06	2.28e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—MTHFR—osteoporosis	5.1e-06	2.27e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—POMC—osteoporosis	4.93e-06	2.2e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL6—osteoporosis	4.82e-06	2.15e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6R—osteoporosis	4.81e-06	2.14e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—MTHFR—osteoporosis	4.8e-06	2.14e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL6—osteoporosis	4.8e-06	2.14e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6—osteoporosis	4.79e-06	2.14e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6—osteoporosis	4.78e-06	2.13e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—MTHFR—osteoporosis	4.76e-06	2.12e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IGF1—osteoporosis	4.74e-06	2.12e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6—osteoporosis	4.72e-06	2.1e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—osteoporosis	4.47e-06	1.99e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ADCY5—osteoporosis	4.43e-06	1.97e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GPX1—osteoporosis	4.41e-06	1.97e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—osteoporosis	4.39e-06	1.96e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP19A1—osteoporosis	4.18e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—osteoporosis	4.16e-06	1.86e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFB1—osteoporosis	4.15e-06	1.85e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—POMC—osteoporosis	4.08e-06	1.82e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MTHFR—osteoporosis	4.07e-06	1.82e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—osteoporosis	3.9e-06	1.74e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—POMC—osteoporosis	3.84e-06	1.71e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—POMC—osteoporosis	3.81e-06	1.7e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—osteoporosis	3.79e-06	1.69e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFB1—osteoporosis	3.78e-06	1.69e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—osteoporosis	3.76e-06	1.68e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFB1—osteoporosis	3.75e-06	1.67e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—osteoporosis	3.71e-06	1.65e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFB1—osteoporosis	3.7e-06	1.65e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—osteoporosis	3.63e-06	1.62e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—osteoporosis	3.51e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFB1—osteoporosis	3.5e-06	1.56e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—osteoporosis	3.45e-06	1.54e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFB1—osteoporosis	3.45e-06	1.54e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ADCY5—osteoporosis	3.42e-06	1.52e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GPX1—osteoporosis	3.4e-06	1.52e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—POMC—osteoporosis	3.26e-06	1.45e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MTHFR—osteoporosis	3.14e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—osteoporosis	3.13e-06	1.39e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—osteoporosis	3.07e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFB1—osteoporosis	3.06e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—osteoporosis	2.85e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—osteoporosis	2.85e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	2.84e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—osteoporosis	2.82e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—osteoporosis	2.79e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—osteoporosis	2.64e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—osteoporosis	2.6e-06	1.16e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—POMC—osteoporosis	2.51e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—osteoporosis	2.31e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—osteoporosis	2.14e-06	9.55e-06	CbGpPWpGaD
